The COVID-19 global pandemic caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection has infected hundreds of millions of individuals …

Background Our understanding of the global scale of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …

Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
critical for virus infection through the engagement of the human ACE2 protein and is a major …

Abstract SARS-CoV-2 501Y. V2 (B. 1.351), a novel lineage of coronavirus causing COVID-
19, contains substitutions in two immunodominant domains of the spike protein. Here, we …

Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan,
China, in December 2019, the novel coronavirus that causes this disease—severe acute …

We identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples …